Stablepharma
Private Company
Total funding raised: $10.3M
Overview
Stablepharma is pioneering the development of fridge-free vaccines and pharmaceuticals through its innovative StablevaX™ thermostabilization platform. The company is advancing a pipeline of reformulated vaccines, with its lead Tetanus-Diphtheria (Td) candidate having completed a Phase 1 clinical trial. By addressing the massive logistical and environmental costs of the global cold chain, Stablepharma targets significant public health impact and commercial opportunity in both developed and emerging markets, supported by grant funding and strategic partnerships.
Technology Platform
StablevaX™ - a proprietary platform technology that reformulates existing vaccines and biologicals into thermostable forms that remain safe and effective at temperatures of 40°C and above.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
The thermostable vaccine space includes competitors like CureVac (mRNA thermostability efforts), various academic and non-profit initiatives (e.g., at PATH), and large vaccine manufacturers investing in improved formulations. Stablepharma's focus on a platform for reformulating existing products, rather than developing novel antigens, is a differentiating approach. Its lead in clinical trials for a fridge-free Td vaccine provides a potential first-mover advantage in a specific niche.